Skip to main content
OpenTrials
Completed

NCT Number: NCT03516019

eFHS Messaging Trial

In this research the investigators will develop and test an innovative scalable mobile health and digital cardiovascular monitoring system within a longitudinal deeply characterized cohort with three components: 1) smartphone application (app) designed to promote adherence, integrate digital and mHealth information, and facilitate communication with participants and researchers; 2) smartwatch activity monitoring using the Apple iWatch; and 3) home blood pressure (BP) monitoring using the Withings blood pressure device.

The objective of the messaging trial is to test the effect of messaging strategies on improving participants' long-term use of and engagement with our selected mobile health technologies and on increasing response rate of survey data collection.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Framingham Heart Study

Boston, Massachusetts, 02118, United States

About this study

The research design includes a cohort eFHS Study and an embedded randomized factorial trial on a subset of the cohort.

For the primary e-cohort, the investigators will build a custom mobile app for use within the Framingham Heart Study (FHS) to digitally collect data, compare it against research clinic-collected data, quantify risk factor burden, and perform CVD risk prediction. The app development will focus on 1) CVD risk factor data that would benefit from more frequent ascertainment than the every four to eight year FHS examination cycles; 2) circumstances where in vivo assessment may be superior to clinic-based assessment; 3) key endpoints of the FHS that are considered FHS landmarks. In addition to the eFHS App, participants will be offered wireless devices (Withings BP) to measure blood pressure and an Apple Watch to measure heart rate and steps per day.

For the messaging trial, the investigators will conduct a randomized factorial trial phase to test the effect of messaging strategies. Participants will be sent a weekly notification through the eFHS app. Participants will be randomly allocated to one of 8 groups defined according to the following: using personalized reminder messaging vs. standard neutral messaging; notification sent on a weekday vs. weekend; notification sent in the morning vs. the evening. The three main comparisons will be simultaneously evaluated according to a 2x2x2 factorial design.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for the eFHS study:

  • Participants of the FHS Third Generation, Omni Group 2, and New Offspring Spouse Cohorts attending the in-person examination 3 with access to a smartphone or home internet access and English speaking/reading.

Specifically for the RCT substudy (re: engagement with select mobile health technologies):

  • English-speaking individual
  • Owns an iPhone with compatible iOS (version 9 or higher);
  • Residence in the United States
  • Provision of permissions for notifications and data sharing with the Research Center
  • Provision of signed and dated informed consent

Exclusion criteria

  • Participants who do not meet the inclusion criteria

Treatment and study plan

personalized notices

Other

The personalized notices take into account if data were received over the previous week, and accordingly encourages the participant to use the device and send her data, or encourages the participant to continue using the device and sending data. A library of personalized notices with alternative motivational content was developed. Each time a notification is sent, it will be drawn at random from the library.

standard notices

Other

The standard notices which are neutral and invite participants to wear the watch daily and to measure their blood pressure weekly.

am notices

Other

notifications sent at 7 am.

pm notices

Other

notifications sent at 7 pm.

weekday notices

Other

notifications sent on Wednesday

weekend notices

Other

notifications sent on Saturday

Primary outcomes

  1. Adherence at 3 months to the weekly BP recording

    Time frame: 3 months

    proportion of participants who submit their weekly blood pressure measurement at 3 months

  2. Adherence at 3 months to the weekly HR recording

    Time frame: 3 months

    proportion of participants who submit their weekly heart rate measurement at 3 months

Secondary outcomes

  1. Adherence at one month to the weekly BP recording

    Time frame: 1 month

    proportion of participants who submit their weekly blood pressure measurement at 1 month

  2. Adherence at one month to the weekly HR recording

    Time frame: 1 month

    proportion of participants who submit their weekly heart rate measurement at 1 month

Other outcomes

  1. Adherence to survey response

    Time frame: 3 months

    proportion of participants who complete the eFHS survey at 3 months

  2. Adherence at 6 months to the weekly BP recording

    Time frame: 6 months

    Comparison between the groups receiving personalized notices to the groups receiving standard notices

  3. Adherence at 6 months to the weekly HR recording

    Time frame: 6 months

    Comparison between the groups receiving personalized notices to the groups receiving standard notices

  4. Adherence at 6 months to survey response

    Time frame: 6 months

    Comparison between the groups receiving personalized notices to the groups receiving standard notices

Sponsors and collaborators

Lead sponsor

Boston University

Other

Collaborators

  • Robert Wood Johnson Foundation

Registry information

Official study title

Messaging Intervention Trial in the Electronic Framingham Heart Study (eFHS)

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
May 4, 2018
Registry last updated
Feb 11, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.